Search - tctmd.com

Displaying 721 - 740 of 1277

Sort: Relevancy | Date

News Industry News

NEW DATA CONTINUE TO SHOW SIGNIFICANT AND SUSTAINED BLOOD PRESSURE REDUCTION WITH BOSTON SCIENTIFIC VESSIX™ RENAL DENERVATION SYSTEM

October 28, 2013

News Conference News TCT 2013

Measuring Response to Renal Denervation Depends on BP Decline, Clinical Relevance

October 28, 2013

News Industry News

Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013

October 28, 2013

News Conference News TCT 2013

Understanding Differences Among New Oral Anticoagulants Should Increase Compliance

October 28, 2013

Presentation TCT 2013

Strategies for Measuring Technical Success to Facilitate Ideal Patient Selection in Renal Denervation

Presenter: Paul Sobotka

October 27, 2013

Presentation TCT 2013

Renal Denervation for Glycemic Control and Obstructive Sleep Apnea: An Update

Presenter: Felix Mahfoud

October 27, 2013

Presentation TCT 2013

Ethanol Injection for Renal Denervation (Ablative Solutions)

Presenter: Tim Fischell

October 27, 2013

Presentation TCT 2013

The Spectrum of Current and Future Renal Denervation Clinical Trials

Presenter: Mehdi Shishehbor

October 27, 2013

Presentation TCT 2013

Selecting the Patient Most Likely to Benefit from Renal Artery Intervention

Presenter: Christopher White

October 27, 2013

Presentation TCT 2013

Renal Revascularization Data Review and Recommendations for Management

Presenter: Jeffrey Olin

October 27, 2013

Presentation TCT 2013

Renal Denervation for Congestive Heart Failure: Current Evidence and Ongoing Studies

Presenter: Justin Davies

October 27, 2013

Presentation TCT 2013

Moving Away From Surrogate Measures: Rationale and Design for a Clinical Outcomes Trial of Renal Artery Denervation (EnligHTNment)

Presenter: Felix Mahfoud

October 27, 2013

Presentation TCT 2013

Is Renal Denervation REALLY READY for Prime Time: A Critical Appraisal

Presenter: Darrel Francis

October 27, 2013

Presentation TCT 2013

How We Should Define "Responsiveness" to Renal Denervation Therapies

Presenter: Krishna Rocha-Singh

October 27, 2013

Presentation TCT 2013

FDA Perspectives: Clinical Trial Regulatory Pathway for Renal Denervation Devices

Presenter: Andrew Farb

October 27, 2013

Presentation TCT 2013

Electrophysiological Considerations for Renal Denervation: Implications for Arrhythmia Control

Presenter: Vivek Reddy

October 27, 2013

Presentation TCT 2013

Device and Clinical Trial Update: Cordis Renal Denervation Approach

Presenter: Marc Sapoval

October 27, 2013

Presentation TCT 2013

Cost-Effectiveness of Catheter-Based Renal Denervation in Severe Treatment Resistant Hypertension

Presenter: Jan Pietzsch

October 27, 2013

Presentation TCT 2013

Chemical Ablation for Renal Denervation (Northwind Technologies)

Presenter: Mark Wholey

October 27, 2013

Presentation TCT 2013

Case Presentation: Hypertension Therapies and Renal Denervation

Presenter: Ajay Kirtane

October 27, 2013

Advertisement

NEW DATA CONTINUE TO SHOW SIGNIFICANT AND SUSTAINED BLOOD PRESSURE REDUCTION WITH BOSTON SCIENTIFIC VESSIX™ RENAL DENERVATION SYSTEM

Measuring Response to Renal Denervation Depends on BP Decline, Clinical Relevance

Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013

Understanding Differences Among New Oral Anticoagulants Should Increase Compliance

Strategies for Measuring Technical Success to Facilitate Ideal Patient Selection in Renal Denervation

Renal Denervation for Glycemic Control and Obstructive Sleep Apnea: An Update

Ethanol Injection for Renal Denervation (Ablative Solutions)

The Spectrum of Current and Future Renal Denervation Clinical Trials

Selecting the Patient Most Likely to Benefit from Renal Artery Intervention

Renal Revascularization Data Review and Recommendations for Management

Renal Denervation for Congestive Heart Failure: Current Evidence and Ongoing Studies

Moving Away From Surrogate Measures: Rationale and Design for a Clinical Outcomes Trial of Renal Artery Denervation (EnligHTNment)

Is Renal Denervation REALLY READY for Prime Time: A Critical Appraisal

How We Should Define "Responsiveness" to Renal Denervation Therapies

FDA Perspectives: Clinical Trial Regulatory Pathway for Renal Denervation Devices

Electrophysiological Considerations for Renal Denervation: Implications for Arrhythmia Control

Device and Clinical Trial Update: Cordis Renal Denervation Approach

Cost-Effectiveness of Catheter-Based Renal Denervation in Severe Treatment Resistant Hypertension

Chemical Ablation for Renal Denervation (Northwind Technologies)

Case Presentation: Hypertension Therapies and Renal Denervation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content